



A new treatment designed to improve survival in patients with liver failure by providing extracorporeal hepatic support continuously for up to five days.

Vital Therapies, Inc. is a biotherapeutic company developing ELAD®, an extracorporeal human hepatic cell-based liver treatment.





The connected, collaborative and streamlined approach in Scotland has enabled rapid start-up of this study at 2 centres of excellence within a 4 month period that included the Christmas holidays. The sites have proven pedigree in this type of trial having contributed to the UK-wide STOPAH trial. The Vital Therapies study ultimately hopes to translate ELAD into a possible new treatment option for liver failure patients who have a high mortality risk."

potentially regenerate, or to maintain

the patient until liver transplantation can

Andrew Henry, VP Clinical Operations, VITAL THERAPIES Inc

occur.

An efficient and responsive infrastructure, enabled this complex study, with intensive resource requirement, to be set up within 4 months from initial contact

- NRS feasibility service identified two sites in Glasgow and Dundee
- Rapid review of study completed via NRS **Permissions Co-ordinating** Centre and negotiation of national standard contract and budget
- Hepatology Clinical Lead provided national oversight, advice and co-ordinated approach to discussions

"Scotland is a world leading location for clinical research as evidenced by its well connected life sciences sector, strong research base, talent pool and streamlined, joined up approach to

"Collaboration and early engagement are critical in complex trials such as VTL-308 and I've been delighted to bring this trial to Scotland offering opportunities for patients to access innovative new treatments in liver disease"

Professor John Dillon, NRS Hepatology Clinical Lead supporting companies."

Julia Brown, Senior Director, Healthcare Life and Chemical Sciences, Scottish Enterprise.



Further information

To discuss placing a trial in Scotland contact Steven Burke, Industry Liaison Manager steven.burke@nrs.org.uk / +44 141 951 5508 or visit www.nrs.org.uk/industry

www.nrs.org.uk



@NHSResearchScot

NHS Research Scotland (NRS) is a partnership of Scottish NHS Boards and the Chief Scientist Office of Scottish Government. Registered Number: GB 236303. Registered address: The Golden Jubilee National Hospital, Fourth Floor East, Agamemnon St, Clydebank, G81 4DY Published by NHS Research Scotland. All rights reserved. Material contained in this publication may not be reproduced in whole or part without prior permission of NHS Research Scotland (or other copyright owners). Whilst every effort is made to ensure that the information given here is accurate, no legal responsibility is accepted for any errors, omissions or misleading statements.